Table 3 Perceived impact of patent linkage system in selected areas
| Â | Total | Group 1 | Group 2 | Group 3 |
|---|---|---|---|---|
Enhanced research and development capability | ||||
  Research on new drugs | -0.54 (0.98) | -0.62 (1.05) | -0.64 (0.88) | -0.14 (0.83) |
  Research on modified new drugs | 0.46 (1.06) | 0.43 (1.00) | 0.55 (1.30) | 0.43 (0.73) |
  Research on the first generic | 1.18 (0.75) | 1.05 (0.65) | 1.36 (0.98) | 1.29 (0.45) |
  Analyze related patents | 0.79 (0.91) | 0.71 (0.76) | 1.18 (0.94) | 0.43 (1.05) |
Increased sales | ||||
  Domestic sales | 0.33 (0.69) | 0.24 (0.68) | 0.36 (0.64) | 0.57 (0.73) |
  Overseas sales | -0.90 (0.84) | -1.10 (0.75) | -0.82 (0.83) | -0.43 (0.9) |
Improved access to medicines | ||||
  Access to new drugs | -0.18 (0.96) | -0.14 (1.08) | -0.36 (0.64) | 0.00 (0.93) |
  Access to generic drugs | 0.38 (0.89) | 0.67 (0.78) | -0.09 (0.79) | 0.29 (1.03) |
Increased employment | ||||
  Patent department | 0.46 (1.01) | 0.29 (0.70) | 0.73 (1.21) | 0.57 (1.29) |
  Research and development department | 0.26 (0.78) | 0.10 (0.68) | 0.55 (0.89) | 0.29 (0.70) |
  Regulatory affairs department | 0.23 (0.80) | 0.05 (0.72) | 0.45 (0.99) | 0.43 (0.49) |
  Pricing and reimbursement department | -0.26 (0.90) | -0.24 (0.68) | -0.27 (1.35) | -0.29 (0.45) |
  Sales and marketing department | -0.15 (0.83) | -0.29 (0.76) | 0.00 (1.04) | 0.00 (0.53) |